跳至主要内容
临床试验/JPRN-UMIN000019616
JPRN-UMIN000019616已完成2 期

Phase II study of neoadjuvant nab-paclitaxel and trastuzumab for ER negative and HER2 positive breast cancer - Neoadjuvant nab-PTX and trastuzumab for ER negative and HER2 positive breast cancer

Osaka Medical College0 个研究点目标入组 18 人开始时间: 2015年11月4日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 70years-old(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1. With history of hypersensitivity reaction for important drug in this study 2. With history of invasive breast cancer 3. Bilateral invasive breast cancer 4. Patients with medical conditions that renders them intolerant to primary chemotherapy and related treatment, including infection, diarrhea, intestinal paralysis, severe Diabetes Mellitus 5. Positive for HBs antigen or HCV antibody 6. With history of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction, poorly controlled hypertension 7. With severe edema 8. With severe peripheral neuropathy 9. With severe psychiatric disorder 10. Pregnant or nursing women 11. The case that is judged to be unsuitable for this study by physician

研究者

相似试验

Phase II study of neoadjuvant nab-paclitaxel and... | 临床试验